Pfiz­er no longer go­ing to con­duct in­ter­im analy­sis for Duchenne gene ther­a­py study by end of year

Pfiz­er no longer plans to read out an in­ter­im analy­sis on its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py pro­gram by the end of the year, it dis­closed at an in­vestor event last week. In­stead, the phar­ma com­pa­ny plans to wait for the fi­nal analy­sis.

The Phase III study for for­dadis­tro­gene mova­parvovec is ex­pect­ed to be com­plet­ed in April, ac­cord­ing to the fed­er­al clin­i­cal tri­als data­base. In Oc­to­ber, Pfiz­er had guid­ed that there could be an in­ter­im analy­sis at year-end and a fi­nal analy­sis in the sec­ond half of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER